$184.96
+1.71 (+0.93%)
CRAI News6 articles
Crypto Kiosk Fraud Prompts Regulatory Crackdown Across U.S. States
Americans lost over $333 million to cryptocurrency ATM scams in 2025, driving lawmakers in at least 15 states to propose stricter rules including registration mandates and enhanced warnings.
Novo Nordisk Rebounds as FDA Vows Crackdown on Wegovy Copycats
Novo Nordisk B shares surged 5.29% after Hims & Hers halted its $49 compounded version of Wegovy, with the FDA pledging action against unauthorized copycats. The stock remains down roughly 20% over five sessions amid pricing uncertainty.
Moutai App Maintenance and Order Crackdown Draw Investor Scrutiny Ahead of Trading
Kweichow Moutai's iMoutai app undergoes overnight maintenance and refunds flagged orders, putting focus on its direct-sales channel as shares prepare for Monday trading.
Hims Halts Compounded GLP-1 Pill as FDA Cracks Down, Molina Plunges on Profit Warning
Hims & Hers discontinues its $49 compounded semaglutide offering following FDA enforcement signals, sending shares down 16%. Molina Healthcare forecasts 2026 profit far below expectations, triggering a 28% stock drop.
FDA Crackdown on Compounded Weight-Loss Drugs Boosts Eli Lilly Shares
Eli Lilly's stock rose 3.7% after the FDA warned Hims & Hers to halt sales of a non-approved compounded GLP-1 weight-loss pill, signaling a regulatory clampdown that may support pricing for branded obesity drugs.
FDA Crackdown on Compounded Weight-Loss Drugs Boosts Eli Lilly Shares
Eli Lilly stock gained 3.7% after FDA signaled action against telehealth firm Hims & Hers over $49 compounded weight-loss alternatives. Regulatory uncertainty continues to impact obesity drug market valuations.